HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.
用户6TNjw1n-83eI
1个月前
121
10
已关闭
DOI:
文献链接:
其他信息:

